This clinical trial is focused on studying the disease known as Generalized Myasthenia Gravis, a condition that causes muscle weakness due to the immune system attacking the communication between nerves and muscles. The study will evaluate a treatment called Gefurulimab, which is administered as a solution for injection. This treatment is being compared to a placebo to assess its effectiveness and safety in managing the symptoms of this disease.
The purpose of the study is to determine how well Gefurulimab works in improving the daily living activities of adults with Generalized Myasthenia Gravis. Participants in the study will receive either the treatment or a placebo and will be monitored over a period of time to observe any changes in their condition. The study aims to see if there is a significant improvement in the ability to perform daily activities and a reduction in muscle weakness.
Throughout the study, participants will undergo regular assessments to track their progress and any changes in their symptoms. The study is designed to provide valuable information on the potential benefits of Gefurulimab for individuals living with Generalized Myasthenia Gravis, contributing to the understanding of how this treatment can help manage the disease.
Austria 
Denmark 
France 
Germany 
Italy 
Poland 
Portugal 
Spain 
The Netherlands 
